Nontoxic doses of suramin enhance activity of doxorubicin in prostate tumors.

@article{Zhang2001NontoxicDO,
  title={Nontoxic doses of suramin enhance activity of doxorubicin in prostate tumors.},
  author={Yu Chu Zhang and Shanjun Song and Fusheng Yang and Jessie L. S. Au and M. Guillaume Wientjes},
  journal={The Journal of pharmacology and experimental therapeutics},
  year={2001},
  volume={299 2},
  pages={
          426-33
        }
}
We recently reported that acidic and basic fibroblast growth factors (aFGF and bFGF) confer a broad-spectrum chemoresistance in solid tumors, and that inhibitors of these proteins enhanced the antitumor activity of several anticancer drugs. The present study investigated the effect of FGF inhibitors on doxorubicin activity in human prostate PC3 tumors. In in vitro studies, conditioned medium (CM) obtained from histocultures of rat MAT-LyLu lung metastases and different combinations of… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 45 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 45 REFERENCES

Suramin in hormone resistant metastatic prostatic cancer: significant anticancer activity but unanticipated toxicity

  • FR Ahmann, J Schwartz, R Dorr, S Salmon
  • Proc Am Soc Clin Oncol
  • 1991
Highly Influential
4 Excerpts

Decetaxel (Taxotere) as monotherapy in the treatment

  • eds, JB Lippincott Company, J Philadelphia.Picus, M Schultz
  • 1999

Similar Papers

Loading similar papers…